The Cost-Effectiveness of Treatments in Non-Cirrhotic Saudi Arabian Patients with Genotype 1 and Genotype 4 Chronic Hepatitis C

• DOI: 10.31080/asps.2020.04.0579
• Publication Date: 2020-09-07T04:55:50Z
• Authors: Mohammad Alowairdhi; Varun Vaidya; Eric Sahloff; Cindy Puffer

Objectives:(1) To estimate the total costs of hepatitis C treatment choices recommended by Saudi Association for Study Liver Diseases and Transplantation (SASLT) based on data from Food Drug Authority (SFDA), (2) develop operationalize decision tree model calculate base case incremental cost-effectiveness ratio (ICER), (3) perform oneway probabilistic sensitivity analyses testing underlying assumptions in model.Methods: A analysis was performed a hypothetical cohort comparing different chronic strategies (SFDA)'s perspective over three-month period using model.Data this study were obtained retrospectively (SFDA) published literature.Costs measured United States Dollars (USD).Life-years gained (Ly) outcomes study.Since SASLT guidelines differ between genotype 1 4, There two separate models each at willingness to pay (WTP) $65,000. Result Discussion: In analysis, comparison interventions showed that both Elbasvir/Grazoprevir Paritaprevir/Ritonavir/Ombitasvir plus Dasabuvir with Ribavirin (3D+RBV) dominated Sofosbuvir Simeprevir Ledipasvir/Sofosbuvir.Against 3D+RBV, ICER $33,796/Ly additional cure.In 4 (2D+RBV) Ledipasvir/Sofosbuvir Simeprevir.The compared are competitive cost effective exception while 2D+RBV is highly 4. Interventions genotypes will be